Page 115 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Alpha-2A receptor agonist and addiction

chlorophenylalanine (p-CPA) attenuation of “conflict” 172. Blum K, Lott L, Baron D, Smith DE, Badgaiyan RD,
behavior. Eur J Pharmacol. 1970;9(3):319-324. Gold MS. Improving naltrexone compliance and outcomes
with putative pro- dopamine regulator KB220, compared to
doi: 10.1016/0014-2999(70)90229-3
treatment as usual. J Syst Integr Neurosci. 2020;7.
169. Veilleux JC, Skinner KD. Smoking, food, and alcohol cues doi: 10.15761/JSIN.1000229
on subsequent behavior: A qualitative systematic review.
Clin Psychol Rev. 2015;36:13-27. 173. Christie MJ, Williams JT, Osborne PB, Bellchambers CE.
Where is the locus in opioid withdrawal? Trends Pharmacol
doi: 10.1016/j.cpr.2015.01.001 Sci. 1997;18(4):134-140.
170. Covey LS, Glassman AH. A meta-analysis of double-blind doi: 10.1016/s0165-6147(97)01045-6
placebo-controlled trials of clonidine for smoking cessation.
Br J Addict. 1991;86(8):991-998. 174. Christie MJ, Williams JT, North RA. Cellular mechanisms
of opioid tolerance: Studies in single brain neurons. Mol
doi: 10.1111/j.1360-0443.1991.tb01860.x Pharmacol. 1987;32(5):633-638.
171. Blum K, Whitney D, Fried L, et al. Hypothesizing that a 175. Colzato L, Elmers J, Xu X, Zhou Q, Hommel B, Beste C.
™
pro-dopaminergic regulator (KB220z Liquid Variant) can Regaining control over opioid use? The potential application
Induce “dopamine homeostasis” and provide adjunctive of auricular transcutaneous vagus nerve stimulation
detoxification benefits in opioid/opioid dependence. Clin to improve opioid treatment in China. Addict Biol.
Med Rev Case Rep. 2016;3(8):125. 2023;28(11):e13343.
doi: 10.23937/2378-3656/1410125 doi: 10.1111/adb.13343

Volume 7 Issue 3 (2024) 21 doi: 10.36922/itps.1918